ASAmirali Soheili

Amirali Soheili

*This is an algorithmically generated author record based on publicly available information.

Amirali Soheili has a total of 77 co-authors. Here are the top co-authors by number of shared publications:

  • Saba Ilkhani

    Center for Surgery and Public Health, Brigham and Women’s Hospital, Harvard Medical School

    2 shared publications
  • Seyed Amir Ahmad Safavi-Naini

    Affiliations Department of Computer Engineering, Data Science and Machine Learning Lab (DML), Sharif University of Technology, Tehran, Iran, Data-Driven and Digital Health (D3M), The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America

    2 shared publications
  • Afsaneh Safarian

    Department of Internal Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    1 shared publication
  • Ali Solhpour

    Department of Anesthesiology, University of Florida, Gainesville, USA

    1 shared publication
  • Amir Ghaffari Jolfayi

    Cardiovascular Research Center, Rajaie Cardiovascular, Medical, and Research Center Iran University of Medical Sciences Tehran Iran

    1 shared publication
  • Amir Sadeghi

    Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases Shahid Beheshti University of Medical Sciences Tehran Iran

    1 shared publication

Latest Publications

  • Open Access

    Preferences for life-sustaining treatments and advance directives among heart failure patients: a systematic review and meta-analysis

    by Shiva Khaleghparast, Saeideh Mazloomzadeh, Aydin Feyzi, Fahimeh Farrokhzadeh, Sanaz Sadeghi, Amirhossein Ghaseminejad-Raeini, Sara Adimi, Amirali Soheili, Samira Chaibakhsh

    Background: Advance directives (ADs) play a fundamental role in guiding end-of-life (EOL) care, yet patient preferences regarding surrogate decision-making, life-sustaining treatments (LSTs), and cardiopulmonary resuscitation (CPR) fluctuate extensively. Understanding these preferences is crucial for person-centered and culturally sensitive advance care planning (ACP), particularly heart failure patients. Methods: A systematic review and meta-analysis were conducted to evaluate patient preferences regarding ADs. Databases including PubMed, Scopus, Web of Science, and Embase were searched for studies published up to March 6, 2024 that reported on preferences related to surrogate decision-making, LSTs, or CPR in patients with heart failure. Data was pooled using a random-effects model. Sensitivity analyses were conducted to assess the influence of outlier studies. Risk of publication bias was evaluated using Begg’s and Egger’s tests. Results: Thirteen studies involving varied international populations were included. The pooled estimate of patients preferring surrogate decision-making was 53.66% (95% CI: 16.9%–90.43%), increasing to 71% (95% CI: 51.64%–91.34%) after excluding an outlier. Preference for receiving LSTs was 48.8% (95% CI: 37.84%–59.77%), increasing to 52.28% (95% CI: 35.95%–59.88%) after exclusion of one study. The pooled proportion of patients preferring to refuse CPR was 43.32% (95% CI: 29.13%–57.52%). Cultural factors, health status, and prior communication influenced these preferences. No significant publication bias was identified. Conclusion: Preferences regarding ADs among patients with heart failure are diverse and influenced by cultural setting, disease morbidity, and prior ACP discussions. A substantial proportion of patients prefer surrogate decision-making and limited life-prolonging interventions. These findings highlight the need for culturally sensitive, personalized ACP that accommodates developing patient values and decision-making roles over time.

  • Comprehensive surgical and medical management of massive fungal endocarditis in a preterm neonate: A rare case of survival and full recovery

    by Reyhaneh Alipoor Rafie, Maedeh Soflaee, Hojjat Mortezaeian, Amirhossein Jalali, Aydin Feyzi, Mohsen Anafje, Amirali Soheili


  • Open Access

    Beyond the Beat, Next‐Generation Sequencing Discovery of Novel RYR2 Gene Variant in Long QT Syndrome

    by Samira Kalayinia, Amir Ghaffari Jolfayi, Amirali Soheili, Majid Maleki, Mohammad Dalili, Mahdieh Soveizi, Saba Komijani

    Background: Long QT syndrome (LQTS) is an inherited cardiac channelopathy marked by QT interval prolongation and increased risk of life‐threatening arrhythmias. While variants in KCNQ1 , KCNH2 , and SCN5A explain most cases, many remain genetically unexplained. This study emphasizes the value of genetic testing in diagnosis and individualized therapy. Methods: A 9‐year‐old boy with recurrent syncope was evaluated for LQTS. Clinical workup included history, physical exam, ECG, echocardiography, exercise testing, electrophysiology studies (EPS), Holter monitoring, and cardiac MRI. Family history was assessed. Genetic testing involved whole‐exome sequencing (WES) and Sanger confirmation, followed by bioinformatic pathogenicity analysis. Results: The boy’s ECG showed a QTc of 470 ms, extending to 500 ms during EPS. No structural cardiac defects were detected. WES revealed a heterozygous missense variant, NM_001035.2:c.12370A > C (p.Ser4124Arg), in the RYR2 gene. In silico tools predicted it to be pathogenic, and Sanger sequencing confirmed it. The variant was also identified in the patient’s mother, who had a history of syncope, but not in the father. The patient responded well to propranolol and remained symptom‐free for 18 months. Conclusion: Identification of a pathogenic RYR2 variant expands the known genetic spectrum of LQTS. The patient’s clinical and familial findings highlight the need to consider RYR2 in genetic testing panels, especially for atypical LQTS cases. Continued research is essential to further clarify the genetics of LQTS and guide targeted management.

  • Open Access

    Visual Transformer and Deep CNN Prediction of High-risk COVID-19 Infected Patients using Fusion of CT Images and Clinical Data

    by Sara Saberi Moghadam Tehrani, Maral Zarvani, Paria Amiri, Reza Azmi, Zahra Ghods, Narges Nourozi, Masoomeh Raoufi, Seyed Amir Ahmad Safavi-Naini, Amirali Soheili, Sara Abolghasemi, et al.

    Despite the globally reducing hospitalization rates and the much lower risks of Covid-19 mortality, accurate diagnosis of the infection stage and prediction of outcomes are clinically of interest. Advanced current technology can facilitate automating the process and help identifying those who are at higher risks of developing severe illness. Deep-learning schemes including Visual Transformer and Convolutional Neural Networks (CNNs), in particular, are shown to be powerful tools for predicting clinical outcomes when fed with either CT scan images or clinical data of patients. This paper demonstrates how a novel 3D data fusion approach through concatenating CT scan images with patients’ clinical data can remarkably improve the performance of Visual Transformer and CNN models in predicting Covid-19 infection outcomes. Here, we explore and represent comprehensive research on the efficiency of Video Swin Transformers and a number of CNN models fed with fusion datasets and CT scans only vs a set of conventional classifiers fed with patients’ clinical data only. A relatively large clinical dataset from 380 Covid-19 diagnosed patients was used to train/test the models. Results show that the 3D Video Swin Transformers fed with the fusion datasets of 64 sectional CT scans+67 (or 30 selected) clinical labels outperformed all other approaches for predicting outcomes in Covid-19-infected patients amongst all techniques (i.e., TPR=0.95, FPR=0.40, F0.5 score=0.82, AUC=0.77, Kappa=0.6). Results indicate possibilities of predicting the severity of outcome using patients’ CT images and clinical data collected at the time of admission to hospital.


  • Open Access

    Epidemiology of COVID‐19 in Tehran, Iran: A Cohort Study of Clinical Profile, Risk Factors, and Outcomes

    by Hamidreza Hatamabadi, Tahereh Sabaghian, Amir Sadeghi, Kamran Heidari, Seyed Amir Ahmad Safavi-Naini, Mehdi Azizmohammad Looha, Nazanin Taraghikhah, Shayesteh Khalili, Keivan Karrabi, Afsaneh Saffarian, et al.

    Background. The outbreak of coronavirus disease 2019 (COVID‐19) dates back to December 2019 in China. Iran has been among the most prone countries to the virus. The aim of this study was to report demographics, clinical data, and their association with death and CFR. Methods. This observational cohort study was performed from 20th March 2020 to 18th March 2021 in three tertiary educational hospitals in Tehran, Iran. All patients were admitted based on the WHO, CDC, and Iran’s National Guidelines. Their information was recorded in their medical files. Multivariable analysis was performed to assess demographics, clinical profile, outcomes of disease, and finding the predictors of death due to COVID‐19. Results. Of all 5318 participants, the median age was 60.0 years, and 57.2% of patients were male. The most significant comorbidities were hypertension and diabetes mellitus. Cough, dyspnea, and fever were the most dominant symptoms. Results showed that ICU admission, elderly age, decreased consciousness, low BMI, HTN, IHD, CVA, dialysis, intubation, Alzheimer disease, blood injection, injection of platelets or FFP, and high number of comorbidities were associated with a higher risk of death related to COVID‐19. The trend of CFR was increasing (WPC: 1.86) during weeks 25 to 51. Conclusions. Accurate detection of predictors of poor outcomes helps healthcare providers in stratifying patients, based on their risk factors and healthcare requirements to improve their survival chance.


  • Open Access

    COVID-19 and acute kidney injury presentation; stages and prognosis

    by Amirali Soheili, Sina Khani, Sadra Montazeri, Arash Shayegh, Misaagh Haji Miragha, Melika Sadat Jameie, Laya Jalilian Khave, Ghazal Sanadgol, Dorsa Shirini, Saba Ilkhani, et al.

    Introduction: Coronavirus disease 2019 (COVID-19) can present with acute kidney injury (AKI). Although the rate of AKI among these patients is not high, their outcome could be much worse than the other patients. Serum creatinine rise along with other laboratory findings may help as a clinical predictor of COVID-19 disease prognosis. Objectives: We aimed to evaluate the incidence and possible predictors of AKI occurrence and its outcome during the COVID-19 pandemic. Patients and Methods: In a retrospective observational study of 946 hospital-admitted patients with confirmed COVID-19 between March 20, 2020 and May 9, 2020, we described AKI incidence and its stages along with their association with demographic data, comorbidities, habitual and past-medical history, and laboratory findings using STATA version 14. Results: The mean age of participants was 55.6 (±18.7) years of which 60.4% were male. The most and least frequent underlying diseases were hypertension and chronic liver disease, 20.1% and 1.5%, respectively. Among patients with AKI, 45.9% had a higher age mean and female sex was more prevalent. In addition, hypertension, ischemic heart disease, diabetes, and chronic renal disease were more common in patients with AKI compared to patients without AKI. Moreover, AKI patients had lower oxygen saturation and mean levels of lymphocytes and higher mean levels of LDH and CKMB in comparison with no AKI group on admission. Overall, 80% of the patients were discharged (i.e. alive), of which 63.7% were non-severe patients and 19.4% of the patients expired during hospitalization. Conclusion: Comorbidities were more prevalent among AKI groups. Female and older patients were more prone to AKI during COVID-19 progression. The level of CK-MB was also higher in AKI group, suggesting probable cardiac injury. Lymphopenia and leukocytosis may be poor-prognostic factors for both AKI and COVID-19.